However, the loss of Ase alone is not sufficient to induce Type II fate in Type I NSCs (Bowman et al., 2008), indicating that Tll acts on additional target genes to mediate this cell fate change and tumour initiation. This evidence concerns the gene ARSL and neoplasm.